CA2938712C - Soluble and immunoreactive variants of htlv capsid antigen p24 - Google Patents

Soluble and immunoreactive variants of htlv capsid antigen p24 Download PDF

Info

Publication number
CA2938712C
CA2938712C CA2938712A CA2938712A CA2938712C CA 2938712 C CA2938712 C CA 2938712C CA 2938712 A CA2938712 A CA 2938712A CA 2938712 A CA2938712 A CA 2938712A CA 2938712 C CA2938712 C CA 2938712C
Authority
CA
Canada
Prior art keywords
htlv
antigens
soluble
relates
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2938712A
Other languages
English (en)
French (fr)
Other versions
CA2938712A1 (en
Inventor
Elke Faatz
Peter Muench
Christian Scholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2938712A1 publication Critical patent/CA2938712A1/en
Application granted granted Critical
Publication of CA2938712C publication Critical patent/CA2938712C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2938712A 2014-02-28 2015-02-26 Soluble and immunoreactive variants of htlv capsid antigen p24 Active CA2938712C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14157165.3 2014-02-28
EP14157165.3A EP2913338A1 (en) 2014-02-28 2014-02-28 Soluable and immunoreactive variants of HTLV capsid antigen p24
PCT/EP2015/053966 WO2015128394A2 (en) 2014-02-28 2015-02-26 Soluble and immunoreactive variants of htlv capsid antigen p24

Publications (2)

Publication Number Publication Date
CA2938712A1 CA2938712A1 (en) 2015-09-03
CA2938712C true CA2938712C (en) 2018-10-23

Family

ID=50184798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938712A Active CA2938712C (en) 2014-02-28 2015-02-26 Soluble and immunoreactive variants of htlv capsid antigen p24

Country Status (7)

Country Link
US (2) US10466242B2 (enExample)
EP (2) EP2913338A1 (enExample)
JP (1) JP6491228B2 (enExample)
CN (1) CN106029687B (enExample)
CA (1) CA2938712C (enExample)
ES (1) ES2662611T3 (enExample)
WO (1) WO2015128394A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108780092A (zh) 2016-03-07 2018-11-09 豪夫迈·罗氏有限公司 抗p53抗体的检测
WO2019164402A1 (en) * 2018-02-26 2019-08-29 Technische Universiteit Eindhoven Bioluminescent biosensor for detecting and quantifying biomolecules
JP2023522278A (ja) * 2020-04-23 2023-05-29 エフ． ホフマン－ラ ロシュ アーゲー 抗体－免疫アッセイでの使用のためのコロナヌクレオカプシド抗原

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564268B2 (ja) * 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
NZ238855A (en) 1990-07-18 1994-03-25 Iaf Biochem Int Peptides, mixtures thereof and compositions useful for detecting htlv-i and htlv-ii infections
CA2117378C (en) * 1992-02-24 2003-04-15 Steven K. H. Foung Htlv-i/htlv-ii assay and method
CA2223235A1 (en) * 1995-06-05 1996-12-12 Abbott Laboratories Detection of htlv antibodies utilizing recombinant proteins
AU736670B2 (en) 1996-09-26 2001-08-02 Medical Research Council Chaperone fragments
JP2000078973A (ja) * 1998-09-03 2000-03-21 Tonen Corp Ｈｔｌｖ−ｉ組換え抗原
PL354122A1 (en) * 1999-08-09 2003-12-29 Tripep Abtripep Ab Pharmaceutical compositions containing tripeptides
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
PL215170B1 (pl) 2001-06-22 2013-10-31 Hoffmann La Roche Sposób wytwarzania rozpuszczalnego kompleksu zawierajacego amyloidogenne bialko docelowe oraz bialko opiekuncze z klasy izomeraz peptydyloprolilowych
DK2112158T3 (da) * 2007-04-20 2012-01-23 Hoffmann La Roche Påvisning af primære infektioner med patogener
EP2127678A1 (en) * 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA as a tool for recombinant protein and enzyme technology

Also Published As

Publication number Publication date
US10466242B2 (en) 2019-11-05
JP6491228B2 (ja) 2019-03-27
EP3110831B1 (en) 2018-01-10
WO2015128394A2 (en) 2015-09-03
US20200033342A1 (en) 2020-01-30
JP2017512200A (ja) 2017-05-18
CA2938712A1 (en) 2015-09-03
EP2913338A1 (en) 2015-09-02
CN106029687B (zh) 2020-07-31
CN106029687A (zh) 2016-10-12
EP3110831A2 (en) 2017-01-04
WO2015128394A3 (en) 2015-11-05
US11567079B2 (en) 2023-01-31
US20170184591A1 (en) 2017-06-29
ES2662611T3 (es) 2018-04-09

Similar Documents

Publication Publication Date Title
Cohen et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
Kim et al. Efficient site-specific labeling of proteins via cysteines
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
Stratov et al. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects
Cheng et al. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting
Ferré et al. Purification of correctly oxidized MHC class I heavy‐chain molecules under denaturing conditions: A novel strategy exploiting disulfide assisted protein folding
WO2007018843A3 (en) Methods and compositions for diagnosis and treatment of influenza
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
Lopez-Soriano et al. Lateral flow immunoassay for on-site detection of Xanthomonas arboricola pv. pruni in symptomatic field samples
AR070168A1 (es) Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
EP2363415A3 (en) H5 subtype-specific binding proteins useful for H5 avian influenza diagnosis and surveillance
Ana‐Sosa‐Batiz et al. HIV‐specific antibody‐dependent phagocytosis matures during HIV infection
CA2938712C (en) Soluble and immunoreactive variants of htlv capsid antigen p24
CA3189270C (en) METHOD FOR DETECTING A PANCREATIC TUMOR, ANTIBODIES AND PANCREATIC TUMOR DETECTION KIT
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
EP4465021A3 (en) Signal amplification in solution-based plasmonic specific-binding partner assays
BR112018073660A2 (pt) anticorpos anti-fator ix pádua
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
Doores et al. 2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
CN104155450B (zh) 梅毒螺旋体IgG抗体生物素亲和素酶联免疫检测试剂盒及其制备方法
Ritthisan et al. SKIK-zipbody-alkaline phosphatase, a novel antibody fusion protein expressed in Escherichia coli cytoplasm
WO2010011775A3 (en) Detection and quantification of antigens
CN103952472A (zh) 用于海豚链球菌lamp-lfd可视化检测的引物和探针及引物和探针的应用
Ranjbar et al. Development of a recombinant nucleocapsid protein‐based ELISA for the detection of IgM and IgG antibodies to SARS‐CoV‐2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160803